Showing 3801-3810 of 8216 results for "".
- Dr. Ted Rosen on JAK Inhibitors for Refractory Granulomatous and Autoimmune Dermatoseshttps://practicaldermatology.com/news/Dr-Ted-Rosen-JAK-Inhibitors-Refractory-Granulomatous-Autoimmune-Dermatoses/2476038/The role of JAK inhibitors in diseases characterized by chronic macrophage–T-cell interactions continues to grow, Theodore Rosen, MD, said at the DEF Essential Resource Meeting 2025 (DERM2025). The discussion focused on granuloma annulare (GA), sarcoidosis, lichen planus (LP), and lupus erythemat
- Dr. Ted Rosen Highlights Oral Lesions in Dermatologyhttps://practicaldermatology.com/news/Dr-Ted-Rosen-Highlights-Oral-Lesions-Dermatology/2476037/Oral lesions represent a diagnostic challenge in dermatology due to their limited morphological variation and overlapping features across conditions. At the DEF Essential Resource Meeting 2025 (DERM2025), Theodore Rosen, MD, reviewed a broad spectrum of oral pathologies, from benign pigmentations
- Study: Many May Avoid Cancer Treatment Due to Skin Side Effectshttps://practicaldermatology.com/news/study-one-third-may-avoid-cancer-treatment-due-to-skin-side-effects/2476010/A new pilot survey revealed that dermatologic side effects (DSEs) from anti-cancer therapies (ACTs) are widely misunderstood and could influence treatment decisions among patients in underserved communities. Researchers from th
- Deucravacitinib Plus Topical C/BD Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/deucravacitinib-plus-topical-cbd-effective-in-moderate-to-severe-psoriasis-analysis/2476009/New research in the Journal of Drugs in Dermatology suggests that adding topical calcipotriene/betamethasone dipropionate (C/BD) foam to oral deucravacitinib therapy improves outcomes and quality of life in patients with moderate to severe chronic plaque p
- Study: Ustekinumab Shows Durability in Real-World Psoriasis Biologic Sequencing Studyhttps://practicaldermatology.com/news/study-ustekinumab-shows-durability-in-real-world-psoriasis-biologic-sequencing-study/2476000/Ustekinumab (Stelara) was associated with the longest treatment duration among biologics used for moderate-to-severe psoriasis, according to results from a recent retrospective real-world analysis. Researchers evaluated health
- FDA Speeds Development of Hair Loss Drug Rezpegaldesleukinhttps://practicaldermatology.com/news/fda-speeds-development-of-nektars-autoimmune-hair-loss-drug/2475953/The FDA has granted Fast Track designation to the investigational biologic rezpegaldesleukin (Nektar Therapeutics) for the treatment of severe-to-very severe alopecia areata (AA) in adults and adolescents aged 12 and older who weigh at least 40 kg.
- Data Show HS Tied to Elevated Depression, Anxiety Riskhttps://practicaldermatology.com/news/data-show-hs-tied-to-elevated-depression-anxiety-risk/2475943/Patients with hidradenitis suppurativa (HS) face elevated risk of developing new-onset depression and anxiety compared with the general population, according to findings from a population-based cohort. The analysis included 1
- Multimodal "Toolkit" Enhances AI Detection of Skin Lesions: Researchershttps://practicaldermatology.com/news/multimodal-dataset-enhances-ai-detection-of-skin-lesions/2475786/A new open-access dataset, MILK10k, provides over 10,000 multimodal images to improve machine learning performance in the diagnosis of both pigmented and non-pigmented skin cancers and simulators. According to researchers publ
- Autoimmune Skin Diseases Linked to Better Cancer Survival: Studyhttps://practicaldermatology.com/news/autoimmune-skin-diseases-linked-to-better-cancer-survival-study/2475516/Patients with autoimmune skin diseases (ASDs) who undergo cancer treatment may experience improved survival outcomes compared to those without ASDs, a new population-based study from Taiwan suggests. Using data derived from Ta
- Study: 90% Would Purchase Red Light Therapy Deviceshttps://practicaldermatology.com/news/study-90-would-purchase-red-light-therapy-devices/2475498/New research published in the Journal of Clinical and Aesthetic Dermatology showed how social media is fueling the growing consumer demand for over-the-counter (OTC) red light therapy (RLT) devices. The authors of the